ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1168

Dermal Fibroblast-derived Exosomes Drive Profibrotic Macrophage Activation in Systemic Sclerosis

Heetaek Yang1, Rajan Bhandari1, Noelle Kosarek2, Jonathan Garlick3, Michael Whitfield4 and Patricia Pioli1, 1Geisel School of Medicine at Dartmouth, Lebanon, NH, 2Dartmouth Geisel School of Medicine, Lebanon, NH, 3Tufts University School of Dental Medicine, Boston, MA, 4Geisel School of Medicine, Lebanon, NH

Meeting: ACR Convergence 2022

Keywords: Bioinformatics, Fibroblasts, Dermal, macrophages, Micro-RNA, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Systemic Sclerosis and Related Disorders – Basic Science Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Macrophage (MØ) activation derives from coordination of signals received in local tissue microenvironments. In prior studies, we demonstrated that cocultured MØs and fibroblasts from patients with systemic sclerosis (SSc) engage in reciprocal activation, and MØs and fibroblasts are co-localized in the skin of SSc patients. Thus, we hypothesize that sustained pro-fibrotic activation of dermal SSc MØs derives from SSc fibroblast-derived secreted mediators.

Methods: Fibroblasts from SSc patients (n=9) or healthy age and sex-matched control (HC) donors (n=7) were isolated from skin biopsies following informed written consent and cultured in complete fibroblast media supplemented with exosome-depleted fetal bovine serum (FBS). Fibroblasts were stimulated with 5 ng/ml TGF-b for 24 hours followed by biochemical isolation of exosomes from cell supernatants. Exosomes were quantified using nanoparticle NanoSight NS300 tracking analysis and exosome purity was assessed by immunoblot for canonical markers. HC monocytes were cultured in RPMI/FBS+M-CSF for 3 days; on day 4, media was replaced with RPMI/exosome-free FBS and HC or SSc exosomes for an additional 2 days. MØs were immunophenotyped using flow cytometry, qRT-PCR and multiplex. To identify fibroblast-derived exosome cargo, microRNAs (miRNAs) were isolated from exosomes followed by library preparation and sequencing. To complement sequencing results, potential fibroblast-derived exosome miRNA regulators were computationally inferred using MiRaGE (miRNA Ranking by Gene Expression) and miRSCAPE.

Results: MØs activated with dermal fibroblast-derived exosomes from SSc patients upregulated surface expression of CD163, CD206, and MHC Class II compared with MØs incubated with healthy control fibroblast exosomes. This pattern of expression was consistent with the previously identified surface marker profile established for human SSc MØs. In addition, SSc fibroblast-derived exosomes elicit elevated levels of secreted IL-6, IL-10, IL-12p40 and TNF from MØs. Combining exosomal miRNA sequencing results with computational prediction algorithms identified several candidate miR regulators of SSc MØ activation: miR-16-5p, miR-100-5p, miR-221-3p, and miR-3666.

Conclusion: In this work, we demonstrate for the first time that human SSc dermal fibroblasts can mediate MØ activation through exosomes. Consistent with prior studies, we show that MØs express surface markers and release mediators associated with both alternative and inflammatory MØ activation. Our results implicate miRs in the induction of SSc MØ activation and may provide additional targets for therapeutic intervention in SSc.


Disclosures: H. Yang, None; R. Bhandari, None; N. Kosarek, None; J. Garlick, None; M. Whitfield, Bristol-Myers Squibb(BMS), Celdara Medical LLC; P. Pioli, Celdara Medical, LLC.

To cite this abstract in AMA style:

Yang H, Bhandari R, Kosarek N, Garlick J, Whitfield M, Pioli P. Dermal Fibroblast-derived Exosomes Drive Profibrotic Macrophage Activation in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/dermal-fibroblast-derived-exosomes-drive-profibrotic-macrophage-activation-in-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/dermal-fibroblast-derived-exosomes-drive-profibrotic-macrophage-activation-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology